Pivotal Phase III Studies Presented During Digestive Disease Week (DDW) Show MMX Mesalamine (Mesavance(TM)) Induced Remission Of Ulcerative Colitis

... Combined results of two pivotalphase III clinical studies (301 and 302) of a novel formulation ofMulti-Matrix System(TM) (MMX) mesalamine, a medication currently underreview by the FDA, Canadian, and EU regulatory agencies, were presentedtoday during DDW at the Los Angeles Convention Center. [click link for full article] ...